epacadostat   Click here for help

GtoPdb Ligand ID: 8221

Synonyms: IDO inhibitor 1 | INCB 24360 | INCB-24360 | INCB024360
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Epacadostat (INCB024360) is an orally bioavailable, potent, small molecule inhibitor of indoleamine-2,3-dioxygenase 1 (IDO1) [1,4], with therapeutic potential in immunodeficiency-associated abnormalities, including cancer.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 5
Rotatable bonds 8
Topological polar surface area 160.09
Molecular weight 436.99
XLogP 1.55
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=NC(=c1[nH]onc1NCCNS(=O)(=O)N)Nc1ccc(c(c1)Br)F
Isomeric SMILES O=N/C(=c\1/[nH]onc1NCCNS(=O)(=O)N)/Nc1ccc(c(c1)Br)F
InChI InChI=1S/C11H13BrFN7O4S/c12-7-5-6(1-2-8(7)13)17-11(18-21)9-10(20-24-19-9)15-3-4-16-25(14,22)23/h1-2,5,16-17,19H,3-4H2,(H,15,20)(H2,14,22,23)/b11-9+
InChI Key YPBKTZBXSBLTDK-PKNBQFBNSA-N
No information available.
Summary of Clinical Use Click here for help
Epacadostat (INCB024360) was advanced to Phase 3 clinical evaluation as an antineoplastic agent in patients with various solid tumours such as melanoma, ovarian, fallopian tube, or primary peritoneal cancers, and myelodysplastic. Click here to link to ClinicalTrials.gov's complete list of INCB024360 trials. Results from the Phase 3 ECHO-301 study (NCT02752074) found no evidence that epacadostat provides any increased benefit compared to pembrolizumab alone in patients with unresectable or metastatic melanoma [2]. This failure has led to a re-evaluation of the utility of IDO1 inhibition as an adjunct to checkpoint inhibition in immuno-oncology [3].